This document outlines a comprehensive 3-phase clinical research program to test the hypothesis that chronic Porphyromonas gingivalis infection (periodontal disease) contributes to Alzheimer's disease (AD) pathogenesis through multiple mechanistic pathways: systemic inflammation, gut microbiome disruption, and impaired microglial amyloid-β clearance[1][2].
The "microbial hypothesis" of AD proposes that chronic infection with specific pathogens may initiate or accelerate neurodegenerative processes. While herpes simplex virus type 1 (HSV-1) has received considerable attention, emerging evidence points to chronic periodontal pathogens as potentially significant contributors[3].
Porphyromonas gingivalis is a Gram-negative anaerobic bacterium implicated in chronic periodontitis, a condition affecting over 50% of adults aged 65 and older. Key evidence linking P. gingivalis to AD includes:
Direct bacterial invasion: P. gingivalis may enter the bloodstream through ulcerated periodontal pockets and cross the blood-brain barrier (BBB), directly infecting brain tissue[6]
LPS-mediated neuroinflammation: Lipopolysaccharide (LPS) from P. gingivalis circulates systemically, activating peripheral monocytes and microglia, leading to chronic neuroinflammation that impairs Aβ clearance[7]
Gut microbiome axis disruption: Periodontal inflammation alters gut microbiome composition via the mouth-gut axis, reducing short-chain fatty acid (SCFA) production and increasing gut permeability, contributing to systemic inflammation[8]
Characterize the association between periodontal disease severity, P. gingivalis burden, and AD biomarkers in a cross-sectional cohort of 300 AD patients.
Inclusion Criteria:
Exclusion Criteria:
Based on expected effect size (r = 0.20 for P. gingivalis antibody vs. CSF biomarkers) with α = 0.05, power = 0.80, and 20% dropout: n = 300
| Category | Biomarkers |
|---|---|
| Periodontal | Pocket depth, CAL, BOP, PI, P. gingivalis DNA (subgingival plaque) |
| Systemic Inflammation | hs-CRP, IL-1β, IL-6, TNF-α |
| AD Core | CSF Aβ42, Aβ40, p-tau181, t-tau (Lumipulse) |
| Microbiome | Gut 16S rRNA sequencing, fecal SCFAs |
| Neuroimaging | MRI hippocampal volume, PET amyloid (if available) |
| Cognition | ADAS-Cog13, MMSE, CDR |
n = 300 AD patients (150 with active periodontal disease, 150 without)
Determine whether intensive periodontal treatment slows cognitive decline and AD biomarker progression in patients with MCI due to AD or mild AD.
Inclusion Criteria:
Exclusion Criteria:
1:1 allocation to Intensive Periodontal Treatment vs. Sham Treatment, stratified by:
Active Arm: Intensive Periodontal Treatment
Control Arm: Sham Treatment
| Endpoint Type | Measures |
|---|---|
| Primary Clinical | ADAS-Cog13 change from baseline at 24 months |
| Primary Biomarker | CSF p-tau181 change from baseline at 12 and 24 months |
| Secondary Clinical | CDR-SB, MMSE, ADL, neuropsychiatric symptoms |
| Secondary Biomarker | CSF Aβ42/40 ratio, plasma p-tau181,NfL |
| Neuroimaging | Hippocampal atrophy rate (MRI, annual) |
| Periodontal | CAL, pocket depth, BOP (confirm treatment efficacy) |
| Inflammatory | hs-CRP, IL-6, TNF-α (quarterly) |
Primary: Mixed-effects linear model (intention-to-treat) with treatment, time, treatment×time interaction, baseline covariates
Secondary:
n = 200 (100 per arm, randomized 1:1)
Evaluate whether adjunctive low-dose antimicrobial therapy (doxycycline) enhances the effect of periodontal treatment on AD biomarkers in patients with evidence of P. gingivalis systemic exposure.
Inclusion Criteria:
Exclusion Criteria:
1:1 allocation to Doxycycline vs. Placebo, stratified by:
Active Arm: Doxycycline 100mg twice daily
Control Arm: Matching placebo
All participants continue:
| Endpoint Type | Measures |
|---|---|
| Primary | CSF p-tau181 change at 12 months |
| Secondary | CSF Aβ42, plasma p-tau181, ADAS-Cog13, inflammatory markers |
| Safety | Adverse events, antibiotic resistance (stool cultures) |
| Biomarker | P. gingivalis antibody titers (efficacy marker) |
n = 100 (50 per arm)
All phases will utilize standardized biomarker collection:
AD Core Biomarkers:
├── CSF: Aβ42, Aβ40, p-tau181, p-tau217, t-tau
├── Plasma: p-tau181, p-tau217, NfL, GFAP
└── Imaging: Amyloid PET, Tau PET, MRI
Infection/Inflammation Biomarkers:
├── Periodontal: P. gingivalis DNA (qPCR), gingipains
├── Systemic: hs-CRP, IL-1β, IL-6, TNF-α, LPS
└── Gut: 16S microbiome, SCFAs, zonulin
A unified database will capture:
Statistical integration across phases using:
Phase 2/3 DSMB (Data Safety Monitoring Board):
| Phase | Design | Duration | Start | Completion |
|---|---|---|---|---|
| 1 | Cross-sectional | 18 months | Month 0 | Month 18 |
| 2 | RCT | 24 months | Month 12 | Month 36 |
| 3 | RCT | 18 months | Month 30 | Month 48 |
Positive findings would:
Negative findings would:
Dominy SS et al. 'Porphyromonas gingivalis in Alzheimer disease: Evidence for disease causation and therapeutic potential'. Sci Adv. 2019. ↩︎ ↩︎
Singhrao SK et al. Porphyromonas gingivalis Periodontal Infection and Its Putative Links with Alzheimer's Disease. Mediators Inflamm. 2015. ↩︎
Sparks Stein P et al. 'Alzheimer disease and the microbiome: Causation or correlation? J Neuroinflammation'. J Neuroinflammation. 2023. ↩︎
Chen C-K et al. 'Association between chronic periodontitis and the risk of Alzheimer''s disease: A meta-analysis'. J Am Geriatr Soc. 2017. ↩︎
Ilievski V et al. Chronic oral application of Porphyromonas gingivalis induces a cerebrovascular pathology and behavioral changes in wild-type mice. J Oral Microbiol. 2023. ↩︎
Poole S et al. The proportion of periodontitis-associated bacteria in the brain reflects oral infection. J Oral Microbiol. 2019. ↩︎
Liu Y et al. LPS induces neuroinflammation and impairs lysosomal function in astrocytes. J Neuroinflammation. 2022. ↩︎
Arai C et al. 'Periodontitis and the gut microbiome in subjects with mild cognitive impairment: A cross-sectional study'. J Alzheimers Dis. 2023. ↩︎
Grenier D et al. 'Role of tetracycline derivatives in neurodegenerative diseases: An update'. J Neuroinflammation. 2021. ↩︎